Roche's Tecentriq adds two months to lung cancer patients' lives: study
A drug cocktail with Roche's Tecentriq added two months to small-cell lung cancer patients' lives, potentially aiding the Swiss company's bid to win approval in a niche disease area before rivals that now dominate the immunotherapy market.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cancer | Cancer & Oncology | Health | Immunotherapy | Lung Cancer | Study | Switzerland Health